Covered recipient · General Payments record
CARLOS CORREA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$6,185.87
- Reported across 214 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,546.98 | 25 |
| Education | $8.90 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $268.70 | 4 |
| Amgen Inc. | $262.35 | 3 |
| Teva Pharmaceuticals USA, Inc. | $237.73 | 2 |
| Lilly USA, LLC | $184.61 | 6 |
| Acerta Pharma LLC | $152.93 | 2 |
| ABBVIE INC. | $132.03 | 2 |
| GlaxoSmithKline, LLC. | $124.99 | 1 |
| Esperion Therapeutics, Inc. | $93.74 | 1 |
| SANOFI-AVENTIS U.S. LLC | $49.80 | 3 |
| DEXCOM, INC. | $49.00 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (26)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $124.99 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103504374 | CMS |
| ABBVIE INC. | $7.04 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103504376 | CMS |
| Amgen Inc. | $125.00 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111554459 | CMS |
| Amgen Inc. | $18.44 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117229308 | CMS |
| Amgen Inc. | $118.91 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117229310 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.94 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105797780 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105746445 | CMS |
| Dexcom, Inc. | $32.89 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153290125 | CMS |
| Dexcom, Inc. | $16.11 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153290127 | CMS |
| Esperion Therapeutics, Inc. | $93.74 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129431772 | CMS |
| GlaxoSmithKline, LLC. | $124.99 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116630482 | CMS |
| Lilly USA, LLC | $19.31 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136084938 | CMS |
| Lilly USA, LLC | $124.99 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136082018 | CMS |
| Lilly USA, LLC | $3.83 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136088796 | CMS |
| Lilly USA, LLC | $4.87 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136086034 | CMS |
| Lilly USA, LLC | $11.07 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136091452 | CMS |
| Lilly USA, LLC | $20.54 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136085526 | CMS |
| Novo Nordisk Inc | $9.81 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097101590 | CMS |
| Novo Nordisk Inc | $8.90 | 05/28/2024 | Education | Undisputed | 01/23/2026 | 1096655210 | CMS |
| Novo Nordisk Inc | $124.99 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096931433 | CMS |
| Novo Nordisk Inc | $125.00 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096634212 | CMS |
| SANOFI-AVENTIS U.S. LLC | $14.42 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139677107 | CMS |
| SANOFI-AVENTIS U.S. LLC | $15.28 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139677131 | CMS |
| SANOFI-AVENTIS U.S. LLC | $20.10 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139677157 | CMS |
| Teva Pharmaceuticals USA, Inc. | $115.66 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151508808 | CMS |
| Teva Pharmaceuticals USA, Inc. | $122.07 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151508938 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.